The cells were treated with 10 ng/ml of recombinant human TNF-α (

The cells were treated with 10 ng/ml of recombinant human TNF-α (Wako) for 3 h. P. gingivalis suspended in OPTI-MEM was added to the Ca9-22 cells at an MOI of 1:100

and further incubated at 37°C in 5% CO2 for 1 h. Unattached bacteria were removed by washing with PBS three times. OPTI-MEM containing 200 μg/ml of metronidazole and 300 μg/ml of gentamicin was added to the plates and they were incubated for 1 h. The cells were washed twice with PBS, and then 1 ml of sterile distilled water per well was added and the cells were suspended persistently by pipetting to disrupt them. The lysates were serially diluted and plated on 5% horse blood agar plates (Poa Media, Eiken PI3K inhibitor drugs Chemical) and then incubated anaerobically at 37°C for 10 days. Colony-forming units (CFU) of invasive P. gingivalis in cells were then enumerated. Silencing of Rab5 gene CHIR-99021 solubility dmso Ca9-22

cells were transfected with 100 pmol siRNA specific for Rab5 (RAB5A-HSS108978, Invitrogen) or control siRNA (Stealth™ RNAi Negative Control Medium GC Duplex, Invitrogen) using Lipofectamine 2000 reagent, as described by the manufacturer (Invitrogen). Then, {Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|buy Anti-infection Compound Library|Anti-infection Compound Library ic50|Anti-infection Compound Library price|Anti-infection Compound Library cost|Anti-infection Compound Library solubility dmso|Anti-infection Compound Library purchase|Anti-infection Compound Library manufacturer|Anti-infection Compound Library research buy|Anti-infection Compound Library order|Anti-infection Compound Library mouse|Anti-infection Compound Library chemical structure|Anti-infection Compound Library mw|Anti-infection Compound Library molecular weight|Anti-infection Compound Library datasheet|Anti-infection Compound Library supplier|Anti-infection Compound Library in vitro|Anti-infection Compound Library cell line|Anti-infection Compound Library concentration|Anti-infection Compound Library nmr|Anti-infection Compound Library in vivo|Anti-infection Compound Library clinical trial|Anti-infection Compound Library cell assay|Anti-infection Compound Library screening|Anti-infection Compound Library high throughput|buy Antiinfection Compound Library|Antiinfection Compound Library ic50|Antiinfection Compound Library price|Antiinfection Compound Library cost|Antiinfection Compound Library solubility dmso|Antiinfection Compound Library purchase|Antiinfection Compound Library manufacturer|Antiinfection Compound Library research buy|Antiinfection Compound Library order|Antiinfection Compound Library chemical structure|Antiinfection Compound Library datasheet|Antiinfection Compound Library supplier|Antiinfection Compound Library in vitro|Antiinfection Compound Library cell line|Antiinfection Compound Library concentration|Antiinfection Compound Library clinical trial|Antiinfection Compound Library cell assay|Antiinfection Compound Library screening|Antiinfection Compound Library high throughput|Anti-infection Compound high throughput screening| expression of Rab5 in the cells was examined by Western blotting using a monoclonal antibody to Rab5. Next, Rab5 siRNA-transfected Ca9-22 cells were incubated with P. gingivalis ATCC 33277 (MOI =100) for 1 h. Viable P. gingivalis in the cells was determined as described above. Immunostaining Treated Ca9-22 cells were fixed with 4% formaldehyde for 10 min. Nonspecific binding of antibodies was

blocked by incubation with 5% sheep serum in 10 mM Tris pH 7.6, 150 mM NaCl, and 0.05% Tween20 (TBS-T) for 1 h, and then the cells were incubated overnight at 4°C with a primary antibody (antiserum for P. gingivalis whole cells, mouse monoclonal antibody specific for ICAM-1) in TBS-T. After washing with buffer A (10 mM Tris pH 7.6, 300 mM NaCl, and 0.5% Tween20) 6 times, the cells were treated with a secondary antibody (anti-rabbit IgG-Alexa 555 or anti-mouse IgG-Alexa 555 and anti-rabbit IgG-Alexa 633) in buffer A for 1 h. Cells were then observed by Selleck HA-1077 a confocal laser scanning microscope (Leica microsystems, Welzlar, Germany). Some Ca9-22 cells were transfected with vectors containing genes of GFP alone (control), GFP-Rab5 (S34N) (inactive form of Rab5), and GFP-Rab5 (Q79L) (active form of Rab5). To clarify whether P. gingivalis cells are in the epithelial cells, a z-series with 0.5 μm-intervals was scanned and images of the x-z and y-z planes were reconstructed with the orthogonal section tool. Western blotting TNF-α-treated and non-treated Ca9-22 cells and THP-1 cells were lysed in SDS-PAGE sample buffer, separated by SDS-PAGE, and transferred onto Immobilon-P Transfer Membranes (Millipore, Billerica, MA). The membranes were blocked with PVDF Blocking Reagent for Can Get Signal (Toyobo) in TBS-T for 1 h at room temperature and then incubated with antibodies to TNFRI, TNFRII, Rab5 and ICAM-1 overnight at 4°C.

Comments are closed.